Exelixis Company

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.

Founded Date: 1994
Headquarters: United States
Technology: Neurological Disorders
Employee Number: 251-500
Industry: Genomic and Epigenominc Instabillity
Estimated Revenue: $100M to $500M
Funding Status: IPO